奥希替尼治疗后非小细胞肺癌表皮生长因子受体突变患者的挽救性化疗。
Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
机构信息
Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan.
出版信息
Anticancer Res. 2020 Apr;40(4):2239-2246. doi: 10.21873/anticanres.14186.
AIM
The current study reports the type of salvage chemotherapy following osimertinib and its treatment efficacy in patients with non-small-cell lung carcinoma (NSCLC) who acquire resistance to osimertinib.
PATIENTS AND METHODS
In this retrospective cohort study, data from the medical charts of 40 patients with NSCLC treated with osimertinib were obtained, primarily focusing on 14 undergoing salvage chemotherapy including epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) or cytotoxic agents immediately following osimertinib. The treatment efficacy of salvage chemotherapy was evaluated.
RESULTS
Five and nine patients received EGFR-TKI and cytotoxic agents following osimertinib, respectively. The overall response rate to EGFR-TKI treatment following osimertinib tended to be lower than that for cytotoxic agents (0% vs. 44.4%). The median progression-free-survival was significantly poorer in patients receiving EGFR-TKI treatment than in those receiving cytotoxic agents.
CONCLUSION
Cytotoxic agent administration should be considered more frequently than EGFR-TKIs for patients with NSCLC resistant to osimertinib.
目的
本研究报告了奥希替尼耐药的非小细胞肺癌（NSCLC）患者接受奥希替尼后进行挽救化疗的类型及其治疗效果。
患者和方法
在这项回顾性队列研究中，我们从接受奥希替尼治疗的 40 名 NSCLC 患者的病历中获取数据，主要关注 14 名在奥希替尼治疗后立即接受挽救化疗的患者，包括表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）或细胞毒药物。我们评估了挽救化疗的治疗效果。
结果
分别有 5 名和 9 名患者在奥希替尼治疗后接受了 EGFR-TKI 和细胞毒药物治疗。奥希替尼治疗后接受 EGFR-TKI 治疗的总体缓解率似乎低于细胞毒药物（0%比 44.4%）。接受 EGFR-TKI 治疗的患者的无进展生存期明显短于接受细胞毒药物治疗的患者。
结论
对于奥希替尼耐药的 NSCLC 患者，应更频繁地考虑使用细胞毒药物而非 EGFR-TKIs。
Zotero 插件